[MATRIX] QoQ Annualized Quarter Result on 30-Sep-2023 [#2]

Stock
[MATRIX] MATRIX CONCEPTS HOLDINGS BHD
Announcement Date
23-Nov-2023
Admission Sponsor
-
Sponsor
-
Financial Year
31-Mar-2024
Quarter
30-Sep-2023 [#2]
Profit Trend
QoQ- -0.44%
YoY- 31.79%
Quarter Report
Latest QR
Upcoming QR
MATRIX's Result
MATRIX's Financial Summary
View:
Show?
Annualized Quarter Result
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
Revenue 1,118,860 1,339,896 1,315,678 1,381,560 1,325,704 1,117,624 1,087,221 1.93%
PBT 324,332 334,055 329,546 342,070 348,888 273,290 271,756 12.52%
Tax -78,336 -85,943 -84,909 -88,448 -94,072 -69,160 -72,336 5.46%
NP 245,996 248,112 244,637 253,622 254,816 204,130 199,420 15.03%
-
NP to SH 242,764 246,472 247,826 257,264 258,408 208,535 202,638 12.81%
-
Tax Rate 24.15% 25.73% 25.77% 25.86% 26.96% 25.31% 26.62% -
Total Cost 872,864 1,091,784 1,071,041 1,127,938 1,070,888 913,494 887,801 -1.12%
-
Net Worth 2,152,319 2,114,779 2,089,751 2,064,725 2,027,184 1,989,644 1,952,103 6.73%
Dividend
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
Div 125,134 125,134 125,134 125,134 125,134 115,749 116,792 4.71%
Div Payout % 51.55% 50.77% 50.49% 48.64% 48.43% 55.51% 57.64% -
Equity
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
Net Worth 2,152,319 2,114,779 2,089,751 2,064,725 2,027,184 1,989,644 1,952,103 6.73%
NOSH 1,251,348 1,251,348 1,251,348 1,251,348 1,251,348 1,251,348 1,251,348 0.00%
Ratio Analysis
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
NP Margin 21.99% 18.52% 18.59% 18.36% 19.22% 18.26% 18.34% -
ROE 11.28% 11.65% 11.86% 12.46% 12.75% 10.48% 10.38% -
Per Share
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
RPS 89.41 107.08 105.14 110.41 105.94 89.31 86.88 1.93%
EPS 19.40 19.70 19.80 20.56 20.64 16.66 16.20 12.78%
DPS 10.00 10.00 10.00 10.00 10.00 9.25 9.33 4.73%
NAPS 1.72 1.69 1.67 1.65 1.62 1.59 1.56 6.73%
Adjusted Per Share Value based on latest NOSH - 1,251,348
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
RPS 89.41 107.08 105.14 110.41 105.94 89.31 86.88 1.93%
EPS 19.40 19.70 19.80 20.56 20.64 16.66 16.20 12.78%
DPS 10.00 10.00 10.00 10.00 10.00 9.25 9.33 4.73%
NAPS 1.72 1.69 1.67 1.65 1.62 1.59 1.56 6.73%
Price Multiplier on Financial Quarter End Date
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
Date 28/06/24 29/03/24 29/12/23 29/09/23 30/06/23 31/03/23 30/12/22 -
Price 1.78 1.80 1.65 1.49 1.41 1.45 1.47 -
P/RPS 1.99 1.68 1.57 1.35 1.33 1.62 1.69 11.52%
P/EPS 9.18 9.14 8.33 7.25 6.83 8.70 9.08 0.73%
EY 10.90 10.94 12.00 13.80 14.65 11.49 11.02 -0.72%
DY 5.62 5.56 6.06 6.71 7.09 6.38 6.35 -7.82%
P/NAPS 1.03 1.07 0.99 0.90 0.87 0.91 0.94 6.29%
Price Multiplier on Announcement Date
30/06/24 31/03/24 31/12/23 30/09/23 30/06/23 31/03/23 31/12/22 CAGR
Date 22/08/24 27/05/24 23/02/24 23/11/23 22/08/23 24/05/23 28/02/23 -
Price 1.89 1.82 1.79 1.61 1.47 1.43 1.49 -
P/RPS 2.11 1.70 1.70 1.46 1.39 1.60 1.71 15.05%
P/EPS 9.74 9.24 9.04 7.83 7.12 8.58 9.20 3.87%
EY 10.26 10.82 11.06 12.77 14.05 11.65 10.87 -3.78%
DY 5.29 5.49 5.59 6.21 6.80 6.47 6.26 -10.62%
P/NAPS 1.10 1.08 1.07 0.98 0.91 0.90 0.96 9.50%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment